COMMUNIQUÉ DE PRESSE publié le 03/03/2026 à 07:00, il y a 6 mois 25 jours SIG Group AG: Full year results 2025 - stable revenue in a challenging market environment; clear roadmap to drive future value creation SIG Group AG reports stable revenue for FY 2025 amidst challenging market conditions. Clear roadmap set for future value creation. Mikko Keto appointed new CEO Revenue Market Conditions SIG Group AG FY 2025 Mikko Keto
COMMUNIQUÉ DE PRESSE publié le 03/03/2026 à 07:00, il y a 6 mois 25 jours Annual results 2025 - Arbonia increases revenue and EBITDA and proposes Christoph Ganz as new Chairman of the Board of Directors Arbonia AG reports 12.3% revenue growth and EBITDA increase in 2025. Christoph Ganz proposed as new Chairman of the Board of Directors Board Of Directors EBITDA Revenue Growth Arbonia AG Christoph Ganz
COMMUNIQUÉ DE PRESSE publié le 03/03/2026 à 07:00, il y a 6 mois 25 jours VERAXA Biotech Receives 99.57% Approval for Merger - Path to NASDAQ Listing Under «VRXA» Cleared VERAXA Biotech gains 99.57% approval for merger with Voyager Acquisition Corp., paving the way for NASDAQ listing. Xlife Sciences AG supported the strategic development Merger Nasdaq Listing Xlife Sciences AG Cancer Therapies VERAXA Biotech
COMMUNIQUÉ DE PRESSE publié le 03/03/2026 à 07:00, il y a 6 mois 25 jours DocMorris AG announces changes to its Board of Directors DocMorris AG announces changes to its Board of Directors, with Prof. Stefan Feuerstein, Dr Christian Mielsch, and Rongrong Hu not standing for re-election, proposing the election of new members at the upcoming Annual General Meeting Board Of Directors Annual General Meeting Personnel Changes DocMorris AG New Members
COMMUNIQUÉ DE PRESSE publié le 03/03/2026 à 07:00, il y a 6 mois 25 jours MindMaze Therapeutics Provides Corporate Update and Publishes March 2026 Investor Presentation MindMaze Therapeutics provides corporate update and publishes March 2026 investor presentation, focusing on expansion in the US and Europe, organizational restructuring, and governance changes Expansion Investor Presentation Corporate Update Neurological Diseases MindMaze Therapeutics
COMMUNIQUÉ DE PRESSE publié le 03/03/2026 à 07:00, il y a 6 mois 25 jours Sandra Maissen becomes partner at Dynamics Group Sandra Maissen joins Dynamics Group as partner, enhancing strategic communications and advocacy capabilities in Switzerland's political arena Partner Strategic Communications Dynamics Group Public Affairs Sandra Maissen
COMMUNIQUÉ DE PRESSE publié le 03/03/2026 à 07:00, il y a 6 mois 25 jours Sandra Maissen rejoint Dynamics Group comme Associée Sandra Maissen rejoint Dynamics Group en tant qu'Associée, renforçant ainsi la présence de l'entreprise à Berne et son rôle en communication stratégique et politique Dynamics Group Communication Stratégique Affaires Publiques Associée Sandra Maissen
COMMUNIQUÉ DE PRESSE publié le 03/03/2026 à 07:00, il y a 6 mois 25 jours SMA Group publishes preliminary, non-audited figures for 2025 as a whole and issues guidance for the 2026 fiscal year SMA Group releases preliminary 2025 figures with sales slightly down at €1,516.0 million and issues 2026 guidance with sales expected between €1,475 million to €1,675 million Sales SMA Group Restructuring Program 2025 Figures 2026 Guidance
COMMUNIQUÉ RÉGLEMENTÉ publié le 03/03/2026 à 07:00, il y a 6 mois 25 jours Thales makes available its 2025 Financial Statements
COMMUNIQUÉ RÉGLEMENTÉ publié le 03/03/2026 à 07:00, il y a 6 mois 25 jours Thales met à disposition ses états financiers 2025
Publié le 28/09/2026 à 17:54, il y a 6 heures 51 minutes Reporting on share buyback transactions carried out between September 21 and September 25, 2026
Publié le 28/09/2026 à 17:54, il y a 6 heures 51 minutes Déclaration de rachats d'actions effectués par la Compagnie de Saint-Gobain entre le 21 et le 25 septembre 2026
Publié le 28/09/2026 à 17:35, il y a 7 heures 11 minutes Déclaration hebdomadaire d'opérations effectuées du 21 au 25 septembre 2026
Publié le 29/09/2026 à 00:00, il y a 46 minutes Medicure Announces Completion of Enrollment in Its MEND-PNPO Phase 3 Clinical Trial
Publié le 28/09/2026 à 23:00, il y a 1 heure 46 minutes CORRECTION FROM SOURCE: Organto Foods Highlights Record First Half Results and Progress on Key Strategic Initiatives
Publié le 28/09/2026 à 15:00, il y a 9 heures 46 minutes Vox to Acquire Silver Royalty over the Sorby Hills Project in Australia
Publié le 28/09/2026 à 14:45, il y a 10 heures 1 minute Clinical Trial of the Oral Drug NV-387 to Treat Ebola Has Started Enrollment and Dosing of Patients Last Week (on or about September 23rd), Says NanoViricides
Publié le 28/09/2026 à 14:30, il y a 10 heures 16 minutes Drilling at Cat Creek Intersects a Copper-Molybdenum Porphyry System Visible Molybdenite-Chalcopyrite Over Significant Core Widths
Publié le 28/09/2026 à 22:14, il y a 2 heures 32 minutes EQS-Adhoc: Extension of the Managing Directors' employment contracts of Carsten Cramer, Lars Ricken and Thomas Treß – Carsten Cramer appointed Chairman of the Management Board
Publié le 28/09/2026 à 19:24, il y a 5 heures 22 minutes EQS-Adhoc: Hapag-Lloyd further raises its earnings outlook for the current financial year
Publié le 28/09/2026 à 19:00, il y a 5 heures 46 minutes PATRIMOINE ET COMMERCE : Déclaration des transactions sur actions propres (Hors contrat de liquidité) réalisées du 21 septembre 2026 au 25 septembre 2026
Publié le 28/09/2026 à 18:00, il y a 6 heures 46 minutes GEVELOT S.A.: Weekly declaration of share buybacks – 09/28/2026 (French only)
Publié le 28/09/2026 à 18:00, il y a 6 heures 46 minutes GEVELOT S.A.: Déclaration hebdomadaire de rachat d'actions 28/09/2026